GlobeNewswire Inc.Oct 29, 9:10 PM ET▲ Positive
Collaborating with Anthropic on improving engineered immune-cell treatments for solid tumors, advancing cancer immunotherapy research.
Generate Biomedicines news
$14.16+2.24%
Close Nov 4, 2026 · split-adjustedArticles · 30 days2English, de-duplicated
Positive2100% of coverage
Neutral00%
Negative00% of coverage
About Generate Biomedicines
No recent articles focused on Generate Biomedicines.
Also mentions GENB
Articles that tag GENB but are mainly about other companies.
GlobeNewswire Inc.Oct 16, 10:00 AM ET▲ Positive
Generate Biomedicines secured a USD 1.2 billion partnership with Zealand Pharma for AI-driven drug discovery, demonstrating market validation of AI-enabled pharmaceutical research and strong commercial interest in their technology platform.
The Motley FoolJul 7, 11:07 AM ET▲ Positive
Stock trading above February IPO price of $16. Company has backing from Nvidia and promising clinical-stage therapeutics candidates, including an asthma treatment in phase 3 trials. Wood's continued investment suggests confidence in long-term growth potential.
The Motley FoolJun 27, 7:23 AM ET▲ Positive
Company is developing innovative AI platform for drug testing that significantly improves success rates and reduces development costs. Nvidia's strategic investment and the company's pipeline of drug candidates in clinical trials demonstrate strong growth potential in a massive market.
Investing.comMay 20, 8:33 AM ETNeutral
Small $10.4 million investment in AI-driven drug discovery, representing minor portfolio allocation and experimental diversification into biotech.
GlobeNewswire Inc.Apr 7, 1:00 PM ET▲ Positive
Lead asset GB-0895 in Phase III trials with enrollment expected by H2 2027; announced initiation of two global Phase III trials (SOLAIRIA-1 and SOLAIRIA-2) for severe asthma treatment.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology